Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.74 |
| ▸ | FNTB | P49356 | 6/20 | 0.74 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311793 | 0.89 | FNTA (0.81) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL14722419 | 0.88 | FNTA (0.80) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL2162004 | 0.87 | FNTA (0.78) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL4736266 | 0.87 | FNTA (0.78) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL2162288 | 0.86 | FNTA (0.74) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL2162264 | 0.86 | FNTA (0.77) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL23452817 | 0.85 | FNTA (0.72) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL17817386 | 0.85 | FNTA (1.00) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL2161763 | 0.85 | FNTA (1.00) | FNTAFNTBSRD5A1SRD5A2USP2 | |
| SCHEMBL1310374 | 0.85 | FNTA (0.85) | FNTAFNTBSRD5A1SRD5A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275680-A1 | NOXEL OXIME DERIVATIVES OF 3, 5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | TROPHOS (FR) | 2011-11-10 | — | — | US | claimed |
| EP-2370071-A1 | NOVEL OXIME DERIVATIVES OF 3,5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | Trophos (FR) | 2011-10-05 | — | — | EP | claimed |
| WO-2010076418-A1 | NOVEL OXIME DERIVATIVES OF 3,5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | TROPHOS (FR) | 2010-07-08 | — | — | WO | claimed |
| US-9115059-B2 | Oxime derivatives of 3,5-seco-4-nor-cholestane, pharmaceutical compositions containing same, and method for preparing same | TROPHOS (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20110275680-A1 | NOXEL OXIME DERIVATIVES OF 3, 5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | TROPHOS (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2370071-A1 | NOVEL OXIME DERIVATIVES OF 3,5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | Trophos (FR) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010076418-A1 | NOVEL OXIME DERIVATIVES OF 3,5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | TROPHOS (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275680-A1 | NOXEL OXIME DERIVATIVES OF 3, 5-SECO-4-NOR-CHOLESTANE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PREPARING SAME | NR1H2, NR1H3, NOX3 | FNTA 737/4885FNTB 968/4885SRD5A1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.